Compare PAHC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | ANAB |
|---|---|---|
| Founded | 1946 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2014 | 2015 |
| Metric | PAHC | ANAB |
|---|---|---|
| Price | $32.07 | $66.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $41.25 | ★ $71.67 |
| AVG Volume (30 Days) | 250.7K | ★ 634.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 1883.33 | 91.02 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $833,350,000.00 | $234,603,000.00 |
| Revenue This Year | $17.03 | N/A |
| Revenue Next Year | $3.82 | $52.14 |
| P/E Ratio | $17.04 | ★ N/A |
| Revenue Growth | 4.12 | ★ 157.01 |
| 52 Week Low | $25.58 | $17.11 |
| 52 Week High | $60.08 | $73.30 |
| Indicator | PAHC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 60.48 |
| Support Level | $30.46 | $52.32 |
| Resistance Level | $34.49 | $68.22 |
| Average True Range (ATR) | 1.22 | 3.78 |
| MACD | 0.46 | 0.61 |
| Stochastic Oscillator | 40.30 | 75.87 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).